Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2010-N-0161]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
 DATES: Submit written comments (including recommendations) on the collection of information by January 20, 2021.
 ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to 
                        *https://www.reginfo.gov/​public/​do/​PRAMain.*
                         Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0498. Also include the FDA docket number found in brackets in the heading of this document.
 FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, 
                        *PRAStaff@fda.hhs.gov*.


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Export of Food and Drug Administration-Regulated Products: Export Certificates OMB Control Number 0910-0498—Extension Sections 801(e) and 802 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 381(e) and 382) pertain to the export of FDA-regulated products and are intended to ease restrictions on exportation. The provisions also require the Agency to issue written export certifications within 20 days of any request. In January 2011, section 801(e)(4)(A) was amended by the FDA Food Safety Modernization Act (Pub. L. 111-353) to provide authorization for export certification for food and animal feed, as well as certain unapproved products. To offset Agency resource expenditures for processing certifications requests, the statute provides that FDA may charge firms a fee not to exceed $175. There are four FDA forms (Form FDA 3613, 3613a, 3613b, and 3613c) related to exporting FDA-regulated products. A description of each form is provided below. To obtain a fillable PDF file of each form, visit 
                    *https://www.fda.gov/​vaccines-blood-biologics/​exporting-cber-regulated-products/​fda-forms-certificates-exporting.*
                     To learn more about how to complete these forms, visit 
                    *https://www.fda.gov/​vaccines-blood-biologics/​exporting-cber-regulated-products/​how-complete-fda-export-certificate-forms.*( print page 83092) Table 1—Certificates and Uses
Type of certificate
Use“Supplementary Information Certificate to Foreign Government Requests“
                             “Exporter's Certification Statement Certificate to Foreign Government“. 
                             “Exporter's Certification Statement Certificate to Foreign Government (For Human Tissue Intended for Transplantation)“.
For the export of products legally marketed in the United States.“Supplementary Information Certificate of Exportability Requests“
                             Exporter's Certification Statement Certificate of Exportability“.
For the export of products not approved for marketing in the United States (unapproved products) that meet the requirements of sections 801(e) or 802 of the FD&C Act.“Supplementary Information Certificate of a Pharmaceutical Product“
                             “Exporter's Certification Statement Certificate of a Pharmaceutical Product“
Conforms to the format established by the World Health Organization and is intended for use by the importing country when the product in question is under consideration for a product license that will authorize its importation and sale or for renewal, extension, amending, or reviewing a license.“Supplementary Information Non-Clinical Research Use Only Certificate“
                             “Exporter's Certification Statement (Non-Clinical Research Use Only)“
For the export of a non-clinical research use only product, material, or component that is not intended for human use and which may be marketed in, and legally exported from the United States under the FD&C Act.
 Appropriate centers within FDA review product information submitted by firms in support of the firms' certificate requests. We rely on respondents to certify their compliance with all applicable requirements of the FD&C Act both at the time the certification request is submitted to FDA and at the time the certification is submitted to the respective foreign government. Information regarding FDA's Export Certificates may be found on our website at 
                    *https://www.fda.gov/​regulatory-information/​search-fda-guidance-documents/​fda-export-certificates.* On September 16, 2020, we submitted an information collection request to the Office of Management and Budget (OMB) to revise certain data elements as may be applicable under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Because Section 3856 of the CARES Act contained immediately effective provisions obligating FDA to review and process certification requests, we requested emergency processing by OMB under 5 CFR 1320.13 for the respective information collection. Our information collection request was granted by OMB on September 29, 2020. Therefore, in accordance with 5 CFR 1320.8(d)(1), we invite comment on the burden we attribute to the information collection, which we estimate as follows: Table 2—Estimated Annual Reporting Burden
                        1
FDA center
Number of 
                             Respondents
Number of 
                             Responses per Respondent
Total Anual 
                             responses
Average burden per 
                             response
Total hoursCenter for Biologics Evaluation and Research
2,651
1
2,651
1
2,651Center for Devices and Radiological Health
11,175
1
11,175
2
22,350Center for Drug Evaluation and Research
3,680
1
3,680
1
3,680Center for Veterinary Medicine
1,925
1
1,925
1
1,925Total




30,6061
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 Based on our current evaluation of the information collection, we have made no adjustments since our last request for OMB review and approval. Dated: December 14, 2020. Lauren K. Roth, Acting Principal Associate Commissioner for Policy.


[FR Doc. 2020-28064 Filed 12-18-20; 8:45 am] BILLING CODE 4164-01-P